Grants and Contributions:

Back to search

Title:

Towards Single-Step manufacturing of LNP Gene Therapy

Agreement Number:

913718

Agreement Value:

$128,600.00

Agreement Date:

Oct 1, 2018 - Sep 30, 2019

Description:

The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to incorporate our fusogenic proteins into lipid nanoparticles using the Precision Nanosystems microfluidic platform. We expect that by pre-formulating one of the lipid components with fusogenic protein, we may be able to reduce the manufacturing to a single step compared to the current 2 step process. This will allow us to significantly improve our encapsulation efficiency and simplify our manufacturing process as we move to the clinic.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Edmonton, Alberta, CA T5J 4P6

Reference Number:

172-2018-2019-Q3-913718

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

816561112

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The total amended value is 11,000 dollars.

Amendment Date

Feb 25, 2019

Recipient's Legal Name:

Entos Pharmaceuticals Inc.

Federal Riding Name:

Edmonton Centre

Federal Riding Number:

48014

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

541710

Amendments:

See Amendments